These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 2194536)
1. How to improve cytotoxic therapy in advanced breast cancer. Bastholt L; Mouridsen HT Acta Oncol; 1990; 29(3):349-55. PubMed ID: 2194536 [TBL] [Abstract][Full Text] [Related]
2. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245 [TBL] [Abstract][Full Text] [Related]
3. Single agent versus combination chemotherapy for metastatic breast cancer. Carrick S; Parker S; Wilcken N; Ghersi D; Marzo M; Simes J Cochrane Database Syst Rev; 2005 Apr; (2):CD003372. PubMed ID: 15846660 [TBL] [Abstract][Full Text] [Related]
4. [Relation dose efficacy in chemotherapy: the example of breast cancer]. Chevallier B; Perrocheau G Bull Cancer; 1995; 82 Suppl 1():9s-15s. PubMed ID: 7626858 [TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
6. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265 [TBL] [Abstract][Full Text] [Related]
7. [Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma]. Thomssen C Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):M102-5. PubMed ID: 8964443 [No Abstract] [Full Text] [Related]
8. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Farquhar C; Basser R; Marjoribanks J; Lethaby A Cochrane Database Syst Rev; 2003; (1):CD003139. PubMed ID: 12535457 [TBL] [Abstract][Full Text] [Related]
9. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Budman DR Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532 [TBL] [Abstract][Full Text] [Related]
10. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study. Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089 [TBL] [Abstract][Full Text] [Related]
11. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353 [TBL] [Abstract][Full Text] [Related]
12. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. Mundt AJ; Sibley GS; Williams S; Rubin SJ; Heimann R; Halpern H; Weichselbaum RR Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):151-60. PubMed ID: 8083108 [TBL] [Abstract][Full Text] [Related]
13. Randomized trials of high dose chemotherapy for breast cancer. Antman KH Biochim Biophys Acta; 2001 Mar; 1471(3):M89-98. PubMed ID: 11250065 [TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. Ghalie R; Richman CM; Adler SS; Cobleigh MA; Korenblit AD; Manson SD; McLeod BC; Taylor SG; Valentino LA; Wolter J J Clin Oncol; 1994 Feb; 12(2):342-6. PubMed ID: 8113841 [TBL] [Abstract][Full Text] [Related]
15. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. Peters WP; Shpall EJ; Jones RB; Olsen GA; Bast RC; Gockerman JP; Moore JO J Clin Oncol; 1988 Sep; 6(9):1368-76. PubMed ID: 3047332 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U; Wilke H; Seeber S Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401 [TBL] [Abstract][Full Text] [Related]
18. Dose intensity as a therapeutic strategy in breast cancer. Osborne CK Breast Cancer Res Treat; 1991 Dec; 20 Suppl():S11-4. PubMed ID: 1687202 [TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy of advanced breast cancer]. Ogawa M Gan To Kagaku Ryoho; 1992 Jun; 19(6):769-74. PubMed ID: 1605652 [TBL] [Abstract][Full Text] [Related]
20. [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. Fujita F; Fujita M; Yamauchi T; Sakamoto Y; Shimozuma K; Inaba H; Taguchi T Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1297-304. PubMed ID: 2953311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]